Validating Plasma Biomarkers for Alzheimer’s Disease Diagnosis
A new study validates clinical cut-points for plasma phosphorylated tau217 (p-tau217), a key biomarker for Alzheimer’s disease (AD). Using two commercial assays (Lumipulse and ALZpath) in biomarker-defined cohorts, researchers established cut-points with high sensitivity and specificity against cerebrospinal fluid and amyloid PET standards. The Lumipulse assay, now available in a UK-accredited clinical laboratory, achieved 95% sensitivity and 97% specificity using a dual cut-point strategy, though it produced indeterminate results in a portion of cases. The study also confirmed the biomarker’s stability across various pre-analytical handling conditions and in individuals with chronic kidney disease, supporting its potential for routine clinical use.
Why it might matter to you:
The validation of accessible blood-based biomarkers like p-tau217 represents a significant shift towards more feasible and widespread screening for neurodegenerative diseases. For researchers in neurodevelopmental and neurological disorders, this advancement highlights the accelerating translation of molecular diagnostics from research to clinical practice. It underscores the growing importance of biomarker research in defining disease states and could inform similar methodological approaches for identifying biomarkers in other complex neurological conditions.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
